Market capitalization | $1.14b |
Enterprise Value | $1.64b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 21.55 |
EV/Sales (TTM) EV/Sales | 2.95 |
P/S ratio (TTM) P/S ratio | 2.06 |
P/B ratio (TTM) P/B ratio | 2.83 |
Revenue growth (TTM) Revenue growth | 23.60% |
Revenue (TTM) Revenue | $555.46m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:
6 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 555 555 |
24%
24%
|
|
Gross Profit | 272 272 |
20%
20%
|
|
EBITDA | 70 70 |
34%
34%
|
EBIT (Operating Income) EBIT | 9.60 9.60 |
79%
79%
|
Net Profit | -8.90 -8.90 |
167%
167%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Head office | United States |
CEO | Nikhil Lalwani |
Employees | 642 |
Founded | 1996 |
Website | www.anipharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.